Dr. Tripathy Discusses Breast Cancer Biomarkers

Video

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Debu Tripathy, MD, professor of medicine and co-leader of the Women’s Cancer Program at the University of Southern California Norris Comprehensive Cancer Center, describes the biomarkers used in clinical decision-making at the time of surgery for early stage breast cancer.

Tripathy describes estrogen receptor (ER), progesterone receptor (PR), and HER2 neu as mandatory in order to make decisions for invasive cancer, for in situ ER and PR are useful to determine if a hormonal therapy will be effective. Trastuzumab is currently being used for mostly all HER2 positive breast cancer with a few exceptions. If there is an expression of even 1% or more of either estrogen or progesterone it calls for the use of hormonal therapy.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD